Discovery of serum metabolites for diagnosis of progression of mild cognitive impairment to Alzheimer's disease using an optimized metabolomics method

0303 health sciences 03 medical and health sciences 3. Good health
DOI: 10.1039/c5ra19349d Publication Date: 2016-01-05T09:30:21Z
ABSTRACT
A nontargeted metabolomics approach was developed to examine metabolic differences in serum samples from the mild cognitive impairment and Alzheimer's disease subjects.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (22)
CITATIONS (60)